Zobrazeno 1 - 10
of 119
pro vyhledávání: '"Katsuhiko Tachibana"'
Autor:
Yoshikatsu Eto, Kohtaro Minami, Norio Sakai, Tatsuyoshi Yamamoto, Tohru Hirato, Yuji Sato, Katsuhiko Tachibana, Mariko Yamaoka, Hiroyuki Sonoda, Torayuki Okuyama
Publikováno v:
Molecular Therapy
Hunter syndrome (mucopolysaccharidosis II [MPS II]), a deficiency of iduronate-2-sulfatase (IDS), causes an accumulation of glycosaminoglycans, giving rise to multiple systemic and CNS symptoms. The currently available therapies, idursulfase and idur
Autor:
Tadao Shibasaki, Ryuji Yamamoto, Sachiho Kida, Masafumi Kinoshita, Hideto Morimoto, Noboru Tanaka, Katsuhiko Tachibana
Publikováno v:
Molecular genetics and metabolism. 125(1-2)
Mucopolysaccharidosis type II (MPS II or Hunter syndrome) is a lysosomal storage disorder caused by a deficiency of iduronate-2-sulfatase (IDS), an enzyme that catabolizes glycosaminoglycans (GAGs) including heparan sulfate (HS) and dermatan sulfate
Autor:
Tohru Hirato, Tatsuyoshi Yamamoto, Kohtaro Minami, Yuji Sato, Norio Sakai, Yoshikatsu Eto, Hiroyuki Sonoda, Torayuki Okuyama, Mariko Yamaoka, Katsuhiko Tachibana
Publikováno v:
SSRN Electronic Journal.
Background: Hunter syndrome (mucopolysaccharidosis II, MPS II) is an X-linked recessive lysosomal storage disease in which a deficiency of iduronate-2-sulfatase causes an accumulation of glycosaminoglycans, giving rise to multiple systemic as well as
Autor:
Takahiro Mochizuki, Naomi Hizuka, Susumu Yokoya, Noriyuki Katsumata, Katsuhiko Tachibana, Akira Shimatsu, Reiko Horikawa, Makoto Anzo, Toshiaki Tanaka, Ke-ita Tatsumi
Publikováno v:
Endocrine journal. 63(10)
Determination of serum growth hormone (GH) levels is mandatory for diagnosis of GH deficiency and excess. In the present study, we, the Study Committee for GH and Its Related Factors, The Foundation for Growth Science, Japan measured GH values in ser
Autor:
Kenji Ohyama, Toru Yorifuji, Hitoshi Kohno, Katsuhiko Tachibana, Hiroaki Takahashi, Susumu Kanzaki, Kenji Fujieda, Reiko Horikawa, Hiroyuki Tanaka, Susumu Yokoya, Toshiaki Tanaka, Keiichi Ozono, Yutaka Igarashi, Yoshikazu Nishi, Hisao Osada, Tomonobu Hasegawa, Kazumichi Onigata, Masamichi Ogawa, Keinosuke Fujita, Toshihiro Tajima, Yoshiki Seino
Publikováno v:
Clinical Pediatric Endocrinology
Background: Patients with Turner syndrome (TS) are prone to having metabolic abnormalities, such as obesity, dyslipidemia, hypertension, hyperinsulinemia and type 2 diabetes mellitus, resulting in increased risks of developing atherosclerotic disease
Autor:
Kenichi Takahashi, Hideto Morimoto, Tohru Hirato, Masafumi Kinoshita, Ryuji Yamamoto, Haruna Takagi, Kohtaro Minami, Hiroyuki Sonoda, Katsuhiko Tachibana, Galina Golovina, Yuri Koshimura, Eiji Yoden
Publikováno v:
Molecular Genetics and Metabolism. 123:S134
Autor:
Yukihiro Hasegawa, Takakuni Tanizawa, Susumu Yokoya, Akira Teramoto, Akira Shimatsu, Toshiaki Tanaka, Yoshikazu Nishi, Kunihiko Hanew, Reiko Horikawa, Toshiro Nagai, Katsuhiko Tachibana, Keinosuke Fujita, Kenji Fujieda, Hiroaki Tanaka
Publikováno v:
Clinical Pediatric Endocrinology
Growth hormone (GH) therapy was approved in 1999 for only GH-deficient Turner syndrome (TS) in Japan. It was subsequently approved for all cases of TS regardless of GH secretory status since 1999. The dose of GH is 1.0 u (0.35 mg)/kg/wk at present, b
Publikováno v:
Acta Paediatrica. 92:698-703
Aim To investigate the final adult heights and pubertal growth patterns in Japanese patients with congenital hypothyroidism (CH) detected by neonatal screening. Methods A retrospective chart review was conducted of female patients >15 y of age (n = 1
Publikováno v:
Acta Paediatrica. 92:1039-1042
Aim To determine the natural growth pattern of Japanese children with Down's syndrome. Methods Longitudinal height data of 85 patients (43 males, 42 females) from birth to final height were analyzed. Based on these data, semi-longitudinal standard gr
Autor:
Kiwamu Imagawa, Hiromi Kinoh, Nana Tsumita, Yuko Kasahara, Shin'ichi Takeda, Takashi Okada, Mutsuki Kuraoka, Tomoko Chiyo, Hironori Okada, Katsuhiko Tachibana
Publikováno v:
Molecular Therapy. 23
Duchenne muscular dystrophy (DMD) is an incurable genetic disease with early mortality that exhibits skeletal muscle weakness with chronic inflammation. Multipotent mesenchymal stromal cells (MSCs) could be a potential therapeutics because of their i